Patrick Dolezal
Stock Analyst at LifeSci Capital
(4.43)
# 1,198
Out of 4,703 analysts
208
Total ratings
42.9%
Success rate
13.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Dolezal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACHV Achieve Life Sciences | Maintained: Buy | $17 | $8.49 | +100.24% | 5 | Sep 3, 2026 | |
| VTVT vTv Therapeutics | Initiated Coverage: Buy | $60 | $33.35 | +79.91% | 1 | Sep 2, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $5 | $1.31 | +281.68% | 13 | Aug 28, 2026 | |
| SLGL Sol-Gel Technologies | Rated: Buy | $184 → $195 | $69.52 | +180.49% | 4 | Aug 22, 2026 | |
| SRZN Surrozen | Maintained: Buy | $46 | $22.76 | +102.11% | 8 | Aug 17, 2026 | |
| KOD Kodiak Sciences | Maintained: Buy | $65 → $85 | $35.36 | +140.38% | 12 | Aug 15, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 → $63 | $38.60 | +63.21% | 13 | Aug 11, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Buy | $12 | $3.86 | +210.88% | 46 | Aug 10, 2026 | |
| OCS Oculis Holding AG | Maintained: Buy | $45 → $41 | $12.17 | +236.89% | 10 | Aug 8, 2026 | |
| MBX MBX Biosciences | Rated: Buy | $91 → $121 | $61.72 | +96.05% | 8 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $104 | $47.34 | +119.69% | 13 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $13.91 | +36.59% | 1 | Jun 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $60 | $90.78 | n/a | 21 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $30.21 | n/a | 25 | Nov 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $14 | $3.83 | n/a | 12 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $17 → $16 | $0.6832 | n/a | 5 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $39 | $39.68 | n/a | 1 | Dec 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 → $25 | $4.78 | n/a | 2 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €10.00 → €25.00 | €4.06 | n/a | 8 | Jun 16, 2020 |
Achieve Life Sciences
Sep 3, 2026
Maintained: Buy
Price Target: $17
Current: $8.49
Upside: +100.24%
vTv Therapeutics
Sep 2, 2026
Initiated Coverage: Buy
Price Target: $60
Current: $33.35
Upside: +79.91%
iBio, Inc.
Aug 28, 2026
Maintained: Buy
Price Target: $5
Current: $1.31
Upside: +281.68%
Sol-Gel Technologies
Aug 22, 2026
Rated: Buy
Price Target: $184 → $195
Current: $69.52
Upside: +180.49%
Surrozen
Aug 17, 2026
Maintained: Buy
Price Target: $46
Current: $22.76
Upside: +102.11%
Kodiak Sciences
Aug 15, 2026
Maintained: Buy
Price Target: $65 → $85
Current: $35.36
Upside: +140.38%
Neurogene
Aug 11, 2026
Maintained: Buy
Price Target: $65 → $63
Current: $38.60
Upside: +63.21%
Rocket Pharmaceuticals
Aug 10, 2026
Maintained: Buy
Price Target: $12
Current: $3.86
Upside: +210.88%
Oculis Holding AG
Aug 8, 2026
Maintained: Buy
Price Target: $45 → $41
Current: $12.17
Upside: +236.89%
MBX Biosciences
Aug 8, 2026
Rated: Buy
Price Target: $91 → $121
Current: $61.72
Upside: +96.05%
Aug 6, 2026
Maintained: Buy
Price Target: $104
Current: $47.34
Upside: +119.69%
Jun 17, 2026
Initiated Coverage: Buy
Price Target: $19
Current: $13.91
Upside: +36.59%
Dec 11, 2023
Rated: Buy
Price Target: $60
Current: $90.78
Upside: n/a
Nov 11, 2023
Maintained: Buy
Price Target: $6
Current: $30.21
Upside: n/a
Aug 10, 2023
Rated: Buy
Price Target: $14
Current: $3.83
Upside: n/a
Mar 9, 2023
Maintained: Buy
Price Target: $17 → $16
Current: $0.6832
Upside: n/a
Dec 11, 2022
Maintained: Buy
Price Target: $39
Current: $39.68
Upside: n/a
Mar 8, 2021
Maintained: Buy
Price Target: $27 → $25
Current: $4.78
Upside: n/a
Jun 16, 2020
Reiterated: Buy
Price Target: €10.00 → €25.00
Current: €4.06
Upside: n/a